Johnson & Johnson expands biotech plant in Schaffhausen

Schaffhausen – The U.S. company Johnson & Johnson is investing 22 million Swiss francs into its Schaffhausen site. Its subsidiary Cilag AG will use the money to expand the biotech pilot plant for the production of sterile products for clinical studies.

Image Credit: Cilag AG

Cilag AG plans to expand its biotech pilot plant in Schaffhausen. The 22-million-franc investment project has now been approved by the parent company Johnson & Johnson, and will include installation of a modern filling machine by 2019 and an additional filling line for vials by 2020.

The expansion aims to increase flexibility and ensure quicker access to products. In operation since 2008, the pilot plant develops and manufactures sterile products for clinical studies.

“The decision to invest close to 22 million francs into this ultra-modern and complex facility once again demonstrates the importance of Cilag AG as a site for strategic development, marketing and production within the Johnson & Johnson group,” according to a Cilag AG statement.

Recommend us

Related Content

How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program